DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for X-linked progressive cerebellar ataxia — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleX-linked progressive cerebellar ataxia maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for x-linked progressive cerebellar ataxia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
gap junction protein beta 1 (GJB1) — GJB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7ZXM · 2.14 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Mutations in the CACNA1A gene, which encodes the CaV2.1 calcium channel, cause X-linked progressive cerebellar ataxia. Two specific missense mutations, C287Y and G293R, were studied in two families with episodic ataxia type 2 and interictal ataxia. In transfected COS-7 cells, these mutant channels showed a marked reduction in current expression and deficient plasma membrane targeting. The authors concluded that protein misfolding and trafficking deficiency, in addition to altered channel function, may contribute to slowly progressive cerebellar ataxia. A 2017 study in a mouse model of SCA6, also caused by CACNA1A mutations, found transient developmental alterations: Purkinje cells had surplus climbing fibre afferent contacts and fired spike trains with elevated rates and precision at postnatal days 10–13, but these abnormalities were no longer observed after day 21, and motor function only deteriorated at about 7 months of age. The authors noted it remains unclear whether these transient defects predispose the motor system to later failure.
A 2020 review of treatable cerebellar ataxias listed metabolic, immune-mediated, inflammatory, and hereditary causes that can be diagnosed and treated with targeted therapies, but did not report any specific treatment for X-linked progressive cerebellar ataxia. A 2020 systematic review of transcranial direct current stimulation (tDCS) in cerebellar ataxia included 8 studies with 81 patients total. The results suggested tDCS over the cerebellum, combined or not with extra-cerebellar areas, might improve motor outcomes, with greater success in less impaired patients. Improvements were seen in gait, stance, oculomotor disorders, finger dexterity, upper limb coordination, and gait speed. The authors concluded that conclusions on effectiveness are premature due to the limited number of studies.
A 2025 review of primary adult-onset neurodegenerative cerebellar ataxias stated that disease-modifying therapies remain limited. For pharmacological approaches, it mentioned omaveloxolone for Friedreich's ataxia and off-label agents such as riluzole, 4-aminopyridine, and varenicline showing subtype-specific benefits, but did not report any drug effective for X-linked progressive cerebellar ataxia. Neuromodulation techniques including tDCS and repetitive transcranial magnetic stimulation have shown early promise in improving motor outcomes. Molecular and gene-based therapies such as antisense oligonucleotides, viral vector delivery, and CRISPR-based strategies are advancing into preclinical and early-phase clinical studies. A 2023 review noted that the rarity of certain ataxia forms limits insights into disease etiology and identification of target pathways, and that lack of suitable models hampers understanding of molecular pathophysiology and testing of novel interventions.
What is still missing: no drug has been shown to slow or halt progression of X-linked progressive cerebellar ataxia in a controlled trial. The available evidence for neuromodulation comes from small, heterogeneous studies. There is no established patient stratification strategy, and the rarity of the condition limits funding for large trials and the development of adequate preclinical models.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2005 · 69 citations
<i>CACNA1A</i> mutations causing episodic and progressive ataxia alter channel trafficking and kinetics
AbstractBACKGROUND: CACNA1A encodes CaV2.1, the pore-forming subunit of P/Q-type voltage-gated calcium channel complexes. Mutations in CACNA1A cause a wide range of neurologic disturbances variably associated with cerebellar degeneration. Functional studies to date focus on electrophysiologic defects that do not adequately explain the phenotypic findings. OBJECTIVE: To investigate whether some missense mutations might interfere with protein folding and trafficking, eventually leading to protein aggregation and neuronal injury. METHODS: The authors studied the functional consequences of two pore missense mutations, C287Y and G293R, in two families with EA2, one newly discovered and the other previously reported. Both mutations caused episodic and interictal ataxia. The biophysical properties of mutant and wild type calcium channels were examined by whole-cell patch-clamp recordings in transfected COS-7 cells. The plasma membrane targeting was visualized by confocal fluorescence imaging on CaV2.1 tagged with green fluorescent protein. RESULTS: The mutant channels exhibited a marked reduction in current expression and deficiencies in plasma membrane targeting. CONCLUSIONS: In addition to altered channel function, the deficiency in protein misfolding and trafficking associated with the C287Y and G293R mutants may contribute to the slowly progressive cerebellar ataxia.
Clinical Parkinsonism & Related Disorders · 2020 · 16 citations · open access
Treatable cerebellar ataxias
AbstractCerebellar ataxic syndrome is a heterogenous class of disorders which can result from a miscellany of causes- genetic or acquired. There are a few metabolic, immune mediated, inflammatory and hereditary causes of ataxia which can be diagnosed from the gamut of possibilities, offering great relief to the ailing patient, their family and the treating physician. A pragmatic algorithm for diagnosing treatable causes of ataxia includes a thorough clinical history, meticulous examination for associated signs and an investigative mind to clinch the diagnosis. With novel diagnostic techniques and targeted therapies, early diagnosis and treatment can lead to favourable outcomes. In this review, diseases presenting predominantly as cerebellar ataxia and are treatable by targeted therapies are discussed.
International Journal of Neuroscience · 2020 · 16 citations
The clinical application of transcranial direct current stimulation in patients with cerebellar ataxia: a systematic review
AbstractAIM: The aim of this review was to investigate the effects of transcranial direct current stimulation (tDCS) on motor function in patients with cerebellar ataxia. MATERIALS AND METHODS: Our systematic review has been performed by searching full-text articles on Pubmed and Scopus. Only studies investigating the motor effects of tDCS in patients with cerebellar ataxias were considered. A qualitative analysis of data was performed, as the methodology of the selected studies was highly heterogeneous. RESULTS: Our search yielded a total of twenty-seven hits. Based on the inclusion criteria, 19 of these were excluded and 89 were retained (number of patients = 81).The results reviewed so far suggest that tDCS over cerebellum combined or not with extra-cerebellar areas might be promising approach to improve motor outcomes, with a greater success in patients less impaired. In particular, it is been shown an improvement in both clinical measures assessing cerebellar deficits (i.e. gait, stance and oculomotor disorders) and performance measures (finger dexterity, upper limb coordination and gait speed). Some of the assessed investigations highlighted a restore effect of cerebellar brain inhibition pathway and resting motor threshold after tDCS. CONCLUSIONS: tDCS could be considered an effective approach to promote plasticity in patient with cerebellar ataxia with significant motor effects. Future studies, with larger sample sizes are needed in order to evaluate the effective tDCS benefits on motor functionality. Due to the limited number of studies available so far, conclusions on the effectiveness of the reported approaches are premature.
Hereditary Ataxias: From Bench to Clinic, where Do We Stand?
AbstractCerebellar ataxias are a wide heterogeneous group of movement disorders. Within this broad umbrella of diseases, there are both genetics and sporadic forms. The clinical presentation of these conditions can exhibit a diverse range of symptoms across different age groups, spanning from pure cerebellar manifestations to sensory ataxia and multisystemic diseases. Over the last few decades, advancements in our understanding of genetics and molecular pathophysiology related to both dominant and recessive ataxias have propelled the field forward, paving the way for in-novative therapeutic strategies aimed at preventing and arresting the progression of these diseas-es. Nevertheless, the rarity of certain forms of ataxia continues to pose challenges, leading to lim-ited insights into the etiology of the disease and the identification of target pathways. Addition-ally, the lack of suitable models hampers efforts to comprehensively understand the molecular foundations of disease pathophysiology and test novel therapeutic interventions. In the following review, we describe the epidemiology, symptomatology, and pathological progression of heredi-tary ataxia, including both the prevalent and less common forms of these diseases. Furthermore, we illustrate the diverse molecular pathways and therapeutic approaches currently undergoing investigation in both pre-clinical studies and clinical trials. Finally, we address the existing and anticipated challenges within this field, encompassing both basic research and clinical endeavors.
Neurotherapeutics · 2025 · 0 citations · open access
Treatment of primary adult-onset neurodegenerative cerebellar ataxias
AbstractPrimary adult-onset neurodegenerative cerebellar ataxias (PANCA) are a clinically and genetically diverse group of disorders for which disease-modifying therapies remain limited. In this review, we provide a comprehensive analysis of therapeutic strategies for PANCA, with a primary focus on clinical trials-randomized controlled and open-label-that have evaluated pharmacological agents, rehabilitation programs, and neuromodulatory interventions. Where clinical trial data are lacking, we incorporate relevant observational studies, expert consensus, and mechanistic rationale to contextualize current practices. Rehabilitation and multidisciplinary care remain foundational across all subtypes and are supported by growing clinical trial evidence. Pharmacological approaches, including omaveloxolone for Friedreich's ataxia and off-label agents such as riluzole, 4-aminopyridine, and varenicline, demonstrate subtype-specific benefits. Neuromodulation techniques, such as transcranial direct current stimulation and repetitive transcranial magnetic stimulation, have shown early promise in improving motor outcomes. In parallel, molecular and gene-based therapies-including antisense oligonucleotides, viral vector delivery systems, and CRISPR-based strategies-are advancing into preclinical and early-phase clinical studies. This evolving therapeutic landscape underscores a shift toward personalized, multimodal care for cerebellar ataxias and highlights the need for continued translational efforts to bridge mechanistic insights with clinical impact.
The Journal of Physiology · 2017 · 0 citations · open access
The pledge, the turn, and the prestige of transient cerebellar alterations in SCA6
AbstractThe cerebellum controls motor behaviour. Accordingly, problems with cerebellar circuitry and function result in a number of debilitating motor diseases. The most extensively studied cerebellar disease is ataxia. The cerebellar ataxias constitute a rapidly growing list of conditions that includes autosomal dominant, autosomal recessive, X-linked and episodic forms. Cerebellar ataxias have various cellular and molecular origins and with this heterogeneity there is also an array of pathological and behavioural manifestations. However, there are also common features in their disease pathophysiology. For example, several spinocerebellar ataxias (SCAs) exhibit similar genetic outcomes involving amino acid repeats such as polyglutamine tract expansions or they share molecular pathways that converge upon neuronal calcium regulation. From a neural systems perspective, the mechanisms of SCA can be separated into two general categories: (1) SCAs with early onset (developmental) motor dysfunction followed by neurodegeneration (e.g. SCA3; Shakkottai et al. 2011) and (2) SCAs involving late onset (adult) neurodegeneration with accompanying behavioural deficits occurring in mature individuals (SCA8; Koob et al. 1999). In this issue of The Journal of Physiology, Jayabal et al. (2017) explored the possibility of a third category. They uncovered transient developmental alterations in ataxia, with neurodegeneration and motor dysfunction starting later in life. To investigate this, the authors performed an elegant study that addressed the mechanisms of ataxia pathogenesis in a mouse model of SCA6. SCA6 is an autosomal dominant ataxia that is caused by mutations in the CACNA1A gene. CACNA1A encodes the α1A subunit of the CaV2.1 P/Q-type voltage-gated calcium channel. In SCA6, the disease-causing mutations induce polyglutamine (CAG) expansions that ultimately result in ataxia with unsteady gait, imbalance and stumbling, in addition to dysarthria, tremor, and eye movement defects. The onset of these symptoms is typically in the 40s, although the age of onset can range from 19 to 71 years old. Since the CACNA1A gene initiates its cerebellar expression in the first week of life in mice, Jayabal et al. (2017) examined whether Sca684Q/84Q mutant mice exhibit developmental alterations using slice electrophysiology, marker expression and motor behaviour paradigms. They found that in developing postnatal day (P)10–P13 mutants, Purkinje cells had surplus climbing fibre afferent contacts and they fired spike trains with elevated rates and precision. Despite these alterations, the authors did not find motor deficits during this period. What was striking was that these alterations were transient, as they were no longer observed after P21. Motor function only deteriorated much later at ∼7 months of age (Jayabal et al. 2015). There are several possible interpretations of the results: The defects may reflect normal developmental variations that are enhanced by the mutation, the alterations are in fact impactful but their effects on behaviour are only realized by the system once the mice approach the later stages of adulthood when multiple physiological stressors arise, the defects are somewhat buried in an already chaotic developing circuit where Purkinje cell dendrites are only halfway through their morphogenesis programme, newly differentiated granule cells are at their peak of migration into the internal granular layer, inhibitory interneurons are still in the process of making their functional connections, mossy fibres still have their own transient connections directly onto Purkinje cells, and the myelination of axons is far from complete. And finally, as the authors speculate, the developing cerebellar nuclei may not yet have the functional capacity to communicate such precise circuit alterations to the rest of the motor system. In the end, these possibilities are probably not mutually exclusive. Our view is that given the transient nature of Purkinje cell firing and innervation defects in developing Sca684Q/84Q mice, it will be important to determine whether these abnormalities are powerful enough to predispose the motor system to fail later in life. However, because CACNA1A is widely expressed throughout the brain, it will be critical to test if Purkinje cell-specific SCA6 mutations impact circuitry in a similar manner to the Sca684Q/84Q mice. In addition, it will be important to know how temporally restricting SCA6 mutations to the developing versus adult cerebellum affect in vivo circuit function and movement in the absence of any potential cumulative effects in the Sca684Q/84Q model. However, there are also molecular questions that arise. For instance, is the CACNA1A mutation associated with an up- or down-regulation of genes involved in compensatory mechanisms that temporarily restore normal circuit function, but are inefficient or unable to persist throughout adulthood? Since it is already known that the CACNA1A gene is involved in different disorders, ranging from familial hemiplegic migraine and epilepsy to SCA6 depending on its mutation (Tottene et al. 2002), it is not unreasonable to hypothesize that each disorder may have a different transcriptional profile at different ages. We speculate that within each disease, misregulated genetic profiles leave temporal specific molecular signatures. It has been reported in SCA6, at later ages, that altered α1ACT binding to enhancer regions (e.g. BTG1 and GRN) results in decreased expression of genes normally regulated to promote Purkinje cell maturation and neurite outgrowth, although α1ACT also impacts climbing fiber innervation (Du et al. 2013). Conducting similar gene expression studies during development may prove fruitful, possibly adding insight into the mechanisms of Purkinje cell miswiring and misfiring, the lack or masking of postnatal motor deficits, or the surprising recovery of circuit function that was beautifully presented here by Jayabal et al. (2017). Lastly, it will be interesting to know if other neurological and neuropsychiatric diseases involve transient alterations, and whether the extent of developmental changes might determine disease severity. The authors have no competing interests to disclose. This work was supported by funds from Baylor College of Medicine and Texas Children's Hospital, BCM IDDRC Grant U54HD083092 (Neurovisualization Core) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and by NINDS R01NS089664.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
